ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) last announced its earnings results on Tuesday, February 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01). On average, analysts expect ESSA Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ESSA Pharma Price Performance
EPIX stock remained flat at $1.71 during midday trading on Tuesday. 5,136 shares of the company’s stock were exchanged, compared to its average volume of 333,638. The company’s 50-day moving average is $1.64 and its 200-day moving average is $1.94. The company has a market cap of $75.91 million, a P/E ratio of -2.48 and a beta of 1.69. ESSA Pharma has a fifty-two week low of $1.40 and a fifty-two week high of $7.88.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Articles
- Five stocks we like better than ESSA Pharma
- Why Invest in 5G? How to Invest in 5G Stocks
- D-Wave Quantum: Hidden Opportunity or Short Seller’s Dream?
- How to Profit From Value Investing
- Uncertainty Creates Opportunity for Tyson Foods Investors
- The 3 Best Fintech Stocks to Buy Now
- Why Wells Fargo Is Buying $40 Billion of Its Own Stock
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
